A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer

Study Identifier:
GO44272
CT.gov Identifier:
NCT05954871
EudraCT Identifier:
N/A
EU Trial (CTIS) Number:
2022-502530-10-00
Study Contact Information:
(210) 593-5651 or [email protected]
Study Complete

Considering participating in a START clinical trial?

Get Started

Study Summary

The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Bowel (Colorectal)
  • Non-Small Cell Lung Cancer
  • Solid Tumor
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    I
    Sex
    Female & Male
    Age
    18+ years
    Study Drug
  • Drug: EXPERIMENTAL: Dose Expansion Stage: CRC
    • Read More
  • Drug: Participants with metastatic CRC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with cetuximab, 500 mg/m\^2, given by IV infusion on Days 1 and 15 of each cycle until disease progression or unacceptable toxicity.
  • Drug: Drug: Cetuximab
  • Drug: Cetuximab, solution for infusion will be administered as specified in each treatment arm.
  • Drug: Drug: GDC-1971
  • Drug: GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
  • Drug: Other Names: RO7517834, RLY-1971
  • Drug: EXPERIMENTAL: Dose Expansion Stage: NSCLC
  • Drug: Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 mg, orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
  • Drug: Drug: Osimertinib
  • Drug: Osimertinib tablets will be administered as specified in each treatment arm.
  • Drug: EXPERIMENTAL: Dose-Finding Stage: Colorectal Cancer (CRC)
  • Drug: Participants with metastatic CRC will receive GDC-1971, at an assigned dose, orally, QD, on Days 1 to 28 days of each 28-day cycle in combination with cetuximab, 500 milligrams per square meter (mg/m\^2), given by IV infusion on Days 1 and 15 of each cycle, until disease progression or unacceptable toxicity.
  • Drug: EXPERIMENTAL: Dose-Finding Stage: Non-Small Cell Lung Cancer (NSCLC)
  • Drug: Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at an assigned dose, orally, once daily (QD), on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 milligrams (mg), orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Study Complete

    Requirements information
    Inclusion criteria
    • * Evaluable or measurable disease per RECIST v1.1
    • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    • * Life expectancy of ≥12 weeks
    • * Adequate hematologic and organ function within 14 days prior to initiation of study Inclusion Criteria for Non-Small Cell Lung Cancer Cohorts
    • * Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the lung that has progressed on/after prior treatment with third-generation epidermal growth factor receptor (EGFR) inhibitor (e.g., osimertinib)
    • * Positive for an EGFR exon 19 deletion or exon 21 L858R mutation
    • * Negative for acquired on-target EGFR alterations Inclusion Criteria for Colorectal Cancer Cohorts
    • * Histologically confirmed metastatic adenocarcinoma of the colon or rectum that has progressed on/after prior treatment with an EGFR inhibitor (e.g., cetuximab or panitumumab)
    • * Negative for kirsten rat sarcoma viral oncogene homolog (KRAS) alterations
    • * Negative for neuroblastoma RAS viral oncogene homolog (NRAS) alterations
    • * Negative for proto-oncogene B-Raf (BRAF) V600E alterations
    • * In lieu of a fresh pre-treatment biopsy, a recently obtained biopsy performed after completion of osimertinib therapy will be acceptable
    Exclusion criteria
    • Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 3 weeks or 5 drug elimination half-lives, whichever is shorter, prior to initiation of study treatment
    • * Treatment with endocrine therapy within 2 weeks prior to initiation of study drug, except for hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for endocrine-sensitive cancers
    • * Significant traumatic injury or major surgical procedure within 4 weeks prior to Cycle 1, Day 1
    • * Positive hepatitis C virus (HCV) antibody test at screening
    • * Positive hepatitis B surface antigen (HBsAg) test at screening
    • * Known HIV infection
    • * Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
    • * Uncontrolled hypercalcemia
    • * Substance abuse, as determined by the investigator, within 12 months prior to screening
    • * Poor peripheral venous access
    • * Inability or unwillingness to swallow pills
    • * Malabsorption syndrome or other condition that would interfere with enteral absorption Chronic diarrhea, short bowel syndrome, or significant upper GI surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), or any active bowel inflammation (including diverticulitis)
    • * Serious infection within 4 weeks prior to screening
    • * History of malignancy within 3 years prior to screening
    • * Known and untreated, or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
    • * Leptomeningeal disease or carcinomatous meningitis
    • * History or presence of an abnormal electrocardiogram (ECG) that is deemed clinically significant by the investigator (e.g., complete left bundle branch block, second- or third-degree atrioventricular heart block) or evidence of prior myocardial infarction
    • * Left ventricular ejection fraction (LVEF) less than the institutional lower limit of normal (LLN) or <50%
    • * History or evidence of ophthalmic disease
    • * History of or active clinically significant cardiovascular dysfunction
    • * History of pulmonary firbrosis, organizing pneumonia, or pneumonitis
    • Other protocol-defined inclusion/exclusion criteria may apply.

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START San Antonio
    San Antonio, TX, United States, 78229
    Investigator
    Amita Patnaik
    Status
    Recruitment Complete
    Condition(s) Treated at Site
    Bowel (Colorectal)
    Non-Small Cell Lung Cancer
    Solid Tumor